Overview

Treatment for Patients With Osteoarthritis (OA) of the Knee

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical response in subjects with symptomatic OA of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular (IA) injection.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Interleukin 1 Receptor Antagonist Protein